Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics
Phase 1
- Conditions
- Advanced Breast Cancer
- Interventions
- Drug: TQB3616
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03850873
Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers
Not Applicable
Completed
- Conditions
- Chronic Hepatitis b
- Interventions
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT03847246
- Locations
- 🇨🇳
Ji'nan Central Hospital, Ji'nan, Shandong, China
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
Phase 1
- Conditions
- Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
- Interventions
- Drug: TQB2450 injectionDrug: Anlotinib
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03825705
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT03800706
- Locations
- 🇨🇳
No.17, panjiayuan nanli, chaoyang district, Beijing, Beijing, China
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2019-05-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 230
- Registration Number
- NCT03777085
- Locations
- 🇨🇳
No. 42 Baiziting Road, Xuanwu District, Nanjing, Jiangsu, China
🇨🇳No.295 Xichang Road, Wuhua District, Kunming, China
🇨🇳No. 82 Cuiyingmen Chengguan District, Lanzhou, China
Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
Not Applicable
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT03771781
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics
Phase 1
Terminated
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: TQB3456
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT03754244
- Locations
- 🇨🇳
No. 241 Huaihai West Road, Xuhui District, Shanghai, Shanghai, Shanghai, China
Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.
Phase 1
- Conditions
- Pharmacokinetic
- Interventions
- Drug: TQ-A3326Drug: placebo
- First Posted Date
- 2018-10-22
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03714568
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma
Phase 3
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: Gemcitabine/Cisplatin
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 336
- Registration Number
- NCT03601975
- Locations
- 🇨🇳
651 Dongfeng Road East, Yuexiu District, Guanzhou, P.R. China, Guangzhou, Guangdong, China
Study of Anlotinib in Patients With Primary Malignant Bone Tumors
- First Posted Date
- 2018-05-17
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03527888
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Beijing Jishuitan Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath